ATA-2271 is under clinical development by Atara Biotherapeutics and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData, Phase I drugs for Malignant Pleural Mesothelioma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ATA-2271’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATA-2271 is under development for the treatment of solid tumors and malignant pleural mesothelioma . It is administered by intrapleural route. It is a next-generation mesothelin-targeted autologous CAR T immunotherapy. The drug candidate is developed using CAR T PD-1 DNR and Novel CAR T 1XX co-stimulation technology. It acts by targeting mesothelin.
Atara Biotherapeutics overview
Atara Biotherapeutics (Atara) is a biopharmaceutical company specialized in T-cell immunotherapy. The company uses its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. It is evaluating its lead candidate, tabelecleucel in Phase III clinical trials for the treatment of epstein-barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline product candidates that are being developed for multiple indications in various stages of clinical trials include ATA188, ATA2271, ATA3219, ATA3271 and other CAR T programs. Atara is headquartered in South San Francisco, California, the US.
For a complete picture of ATA-2271’s drug-specific PTSR and LoA scores, buy the report here.